Navigation Links
BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform
Date:7/22/2014

CAMBRIDGE, Massachusetts og SHENZHEN, Kina, 22. juli 2014 /PRNewswire/ -- BGI Tech Solutions Co., LTD, (BGI Tech), et datterselskab af BGI, verdens største genomics-organisation, annoncerede den globale lancering af en ny human whole exome-sekvenseringstjeneste baseret på Complete Genomics brancheførende platform.

Complete Genomics, højt anset i branchen for at levere patenterede sekvenseringsteknologier med 99,999 % præcision og højfølsom registrering af alle typer varianter, blev købt af BGI i 2013. Mere end 15.000 genomer er sekvenseret og analyseret på Complete Genomics platform til dato. BGI med sin omfattende genom- og exome-sekvenseringsekspertise har forbedret Complete Genomics platform yderligere til nu at kunne levere solide og hurtige human whole exome-sekvenseringstjenester, der udnytter de iboende styrker i den platform.

Whole exome-sekvensering på Complete Genomics platform, der bliver tilgængelig i dag til en introduktionspris på kun USD 599 pr. prøve indtil slutningen af 2014, garanterer 100X gennemsnitlig sekvenseringsdybde for målregioner og omfatter analyse for SNP/InDel-kald og anmærkning samt SNP-validering. Derudover leverer BGI Tech en dedikeret arbejdsproces og pipeline, som adresserer design og udfordringer for studier af kræft, der muliggør følsom registrering af somatiske varianter ved tilstedeværelse af tumorheterogenitet.

Yingrui Li, adm. direktør for BGI Tech, sagde, "Vi er glade for at kunne stille denne ekstremt nøjagtige til rådighed for vores mere end 30.000 kunder over hele verden og til det globale forskningssamfund Vi er i øjeblikket ved at udvikle yderligere applikationer til denne platform, f.eks. transkriptomanalyse og genotype ved sekvensering og ser frem til at annoncere disses tilgængelighed snart."

Yderligere oplysninger fås på bgitechsolutions.com/complete-genomics-offers.

Om BGI Tech

BGI Tech, et datterselskab af BGI, verdens største genomics-organisation, leverer løsninger til sekvensering og bioinformatiktjenester til globale biomedicinske, landbrugsrelaterede og miljøkunder. Med branchens mest omfattende avancerede teknologier leverer BGI Tech resultater, der er hurtige, billige og af høj kvalitet, som gør det muligt for forskere at opnå videnskabelige gennembrud. BGI Tech har leveret førsteklasses tjenester til mere end 10.000 forskningsinstitutter og 30.000 videnskabspartnere, som har resulteret i mere end 600 publikationer, herunder 100 i de bedste magasiner som Nature og Science. Yderligere oplysninger fås på bgitechsolutions.com.

Kontakter

Bicheng Yang, Ph.D.
Public Communication Officer
BGI
+86-755-82639701
yangbicheng@genomics.cn

www.genomics.cn

Joyce Peng, Ph.D.
Marketing Director
BGI Tech & BGI Americas
+1-626-222-5584
joyce.peng@bgiamericas.com

www.bgitechsolutions.com

 


'/>"/>
SOURCE BGI Tech Solutions Co., LTD.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Integrated 3-D Imaging Facilitates Human Face Transplantation
2. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
3. Singapore scientists lead human embryonic stem cell study
4. AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited
5. ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012
6. Cepheid Welcomes Senior Vice President of Human Resources
7. deCODE Genetics, in Collaboration with Academic Colleagues, Discovers Three Variants in the Sequence of the Human Genome that Affect the Risk of Thyroid Cancer
8. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
9. Successful human tests for first wirelessly controlled drug-delivery chip
10. First successful human results achieved: Implantable wireless microchip drug delivery device
11. Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
Breaking Biology News(10 mins):